中、重度特应性皮炎的诊断和治疗进展

doi:10.3760/cma.j.issn.0412-4030.2018.01.025

摘要/Abstract

摘要：

特应性皮炎（AD）是一种慢性、瘙痒性、炎症性皮肤病。全世界的患病率成人达2% ~ 5%，儿童达10% ~ 20％［1］，其中20%属于中、重度［2］。AD发病机制复杂，涉及免疫系统过度活化、上皮屏障功能障碍和皮肤微生物群失调等诸多方面［3?5］。轻度患者可外用润肤剂、糖皮质激素（简称激素）或钙调磷酸酶抑制剂治疗［6］，中、重度患者常需联合免疫抑制剂甚至生物制剂治疗［7］。AD诊断标准众多，如Hanifin和Rajka标准、Williams标准等［8］，但对于中、重度AD的诊断目前尚无统一标准。现从近年来国内外常用的AD诊疗指南入手，结合近年中、重度AD患者进行的临床试验，对中、重度AD的诊断标准进行评价并对其治疗进展进行概述……

孙晓丽李邻峰. 中、重度特应性皮炎的诊断和治疗进展[J]. 中华皮肤科杂志, 2018, 51(1): 72-75.

Xiao-Li SUN. Diagnosis and treatment of moderate-to-severe atopic dermatitis[J]. Chinese Journal of Dermatology, 2018, 51(1): 72-75.

参考文献 35

［1］	Kraft M, Worm M. Dupilumab in the treatment of moderate⁃to⁃severe atopic dermatitis［J］. Expert Rev Clin Immunol, 2017, 13（4）: 301⁃310. DOI: 10.1080/1744666X.2017.1292134.<br />
［2］	Hamilton JD, Suárez⁃Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate⁃to⁃severe atopic dermatitis［J］. J Allergy Clin Immunol, 2014, 134（6）: 1293⁃1300. DOI: 10.1016/j.jaci.2014.10.013.<br />
［3］	Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2016, 138（2）: 336⁃349. DOI: 10.1016/j.jaci.2016.06.010.<br />
［4］	Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation［J］. Immunol Rev, 2011, 242（1）: 233⁃246. DOI: 10.1111/j.1600⁃065X.2011.01027.x.<br />
［5］	Williams MR, Gallo RL. The role of the skin microbiome in atopic dermatitis［J］. Curr Allergy Asthma Rep, 2015, 15（11）: 65. DOI: 10.1007/s11882⁃015⁃0567⁃4.<br />
［6］	Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. management and treatment of atopic dermatitis with topical therapies［J］. J Am Acad Dermatol, 2014, 71（1）: 116⁃132. DOI: 10.1016/j.jaad.2014. 03.023.<br />
［7］	Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. management and treatment with phototherapy and systemic agents［J］. J Am Acad Dermatol, 2014, 71（2）: 327⁃349. DOI: 10.1016/j.jaad.2014.03. 030.<br />
［8］	张建中. 特应性皮炎的诊断标准发展及评价［J］. 中华皮肤科杂志, 2017, 50（1）: 67⁃69. DOI: 10.3760/cma.j.issn.0412⁃4030. 2017.01.025.<br />
［9］	Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients［J］. J Eur Acad Dermatol Venereol, 2016, 30（5）: 729⁃747. DOI: 10.1111/jdv.13599.<br />
［10］	Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2010, 24（3）: 317⁃328. DOI: 10.1111/j.1468⁃3083.2009.03415.x.<br />
［11］	Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema （atopic dermatitis） part I［J］. J Eur Acad Dermatol Venereol, 2012, 26（8）: 1045⁃1060. DOI: 10.1111/j.1468⁃3083. 2012.04635.x.<br />
［12］	Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema （atopic dermatitis） Part II［J］. J Eur Acad Dermatol Venereol, 2012, 26（9）: 1176⁃1193. DOI: 10.1111/j. 1468⁃3083.2012.04636.x.<br />
［13］	Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis［J］. J Am Acad Dermatol, 2014, 70（2）: 338⁃351. DOI: 10.1016/j.jaad.2013.10.010.<br />
［14］	Saeki H, Nakahara T, Tanaka A, et al. Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016［J］. J Dermatol, 2016, 43（10）: 1117⁃1145. DOI: 10.1111/1346⁃8138. 13392.<br />
［15］	中华医学会皮肤性病学分会免疫学组、特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2014版）［J］. 中华皮肤科杂志, 2014, 47（7）: 511⁃514. DOI: 10.3760/cma.j.issn.0412⁃4030. 2014.07.018.<br />
［16］	Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. Exp Dermatol, 2017, 26（1）: 28⁃35. DOI: 10.1111/exd.13112.<br />
［17］	Wong SM, Ng TG, Baba R. Efficacy and safety of sodium hypochlorite （bleach） baths in patients with moderate to severe atopic dermatitis in Malaysia［J］. J Dermatol, 2013, 40（11）: 874⁃880. DOI: 10.1111/1346⁃8138.12265.<br />
［18］	Kim HS, Lee JH, Roh KH, et al. Clinical Trical of human umbilical cord blood⁃derived stem cells for the treatment of moderate⁃to⁃severe atopic dermatatitis: phase I/IIa studies［J］. Stem Cells, 2017, 35（1）: 248⁃255. DOI: 10.1002/stem.2401.<br />
［19］	Edwards AM, Bibawy D, Matthews S, et al. Long⁃term use of a 4 sodium cromoglicate cutaneous emulsion in the treatment of moderate to severe atopic dermatitis in children［J］. J Dermatolog Treat, 2015, 26（6）: 541⁃547. DOI: 10.3109/09546634.2015. 1034077.<br />
［20］	Mehrbania M, Choopani R, Fekri A, et al. The efficacy of whey associated with dodder seed extract on moderate⁃to⁃severe atopic dermatitis in adults: a randomized, double⁃blind, placebo⁃controlled clinical trial［J］. J Ethnopharmacol, 2015, 172: 325⁃332. DOI: 10.1016/j.jep.2015.07.003.<br />
［21］	Nicol NH, Boguniewicz M, Strand M, et al. Wet wrap therapy in children with moderate to severe atopic dermatitis in a multidisciplinary treatment program［J］. J Allergy Clin Immunol Pract, 2014, 2（4）: 400⁃406. DOI: 10.1016/j.jaip.2014.04.009.<br />
［22］	Gu SX, Zhang AL, Coyle ME, et al. Chinese herbal medicine granules （PTQX） for children with moderate to severe atopic eczema: study protocol for a randomised controlled trial［J］. Trials, 2015, 16: 294. DOI: 10.1186/s13063⁃015⁃0806⁃y.<br />
［23］	孙彩虹, 顾恒. 不同国家和地区特应性皮炎治疗指南解读［J］. 中华皮肤科杂志, 2017, 50（03）: 215⁃218. DOI: 10.3760/cma.j.issn.0412⁃4030.2017.03.017.<br />
［24］	Rodenbeck DL, Silverberg JI, Silverberg NB. Phototherapy for atopic dermatitis［J］. Clin Dermatol, 2016, 34（5）: 607⁃613. DOI: 10.1016/j.clindermatol.2016.05.011.<br />
［25］	Nicole NH, Boguniewicz M. Wet wrap therapy in moderate to severe atopic dermatitis［J］. Immunol Allergy Clin North Am, 2017, 37（1）: 123⁃139. DOI: 10.1016/j.iac.2016.08.003.<br />
［26］	Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate⁃to⁃severe atopic dermatitis: a systematic review［J］. J Allergy and Clin Immunol, 2014; 133（2）: 429⁃438. DOI: 10.1016/j.jaci.2013.07.049.<br />
［27］	FDA approves new eczema drug Dupixent. March 28, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549078.htm.<br />
［28］	Saeki H, Kabashima K, Tokura Y, et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double⁃blind, placebo⁃controlled, phase II study［J］. Br J Dermatol, 2017, DOI: 10.1111/bjd.15493.<br />
［29］	Heratizadeh A, Werfel T. Anti⁃inflammatory therapies in atopic dermatitis［J］. Allergy, 2016, 71（12）: 1666⁃1675.DOI: 10.1111/all.13065.<br />
［30］	Saleem MD, Oussedik E, D′Amber V, et al. Interleukin⁃31 pathway and its role in atopic dermatitis: a systematic review［J］. J Dermatolog Treat, 2017, 2: 1⁃9. DOI: 10.1080/09546634.2017. 1290205.<br />
［31］	Ruzicka T, Hanifin JM, Furue M, et al. Anti⁃Interleukin⁃31 Receptor a antibody for atopic dermatitis［J］. N Engl J Med, 2017, 376: 826⁃835. DOI: 10.1056/NEJMoa1606490.<br />
［32］	Montes⁃Torres A, Llamas⁃Velasco M, Pérez⁃Plaza A, et al. Biological treatments in atopic dermatitis［J］. J Clin Med, 2015, 4（4）: 593⁃613. DOI: 10.3390/jcm4040593.<br />
［33］	Guttman⁃Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopicdermatitis［J］. Expert Opin Biol Ther, 2013, 13（4）: 549⁃561. DOI: 10.1517/14712598.2013.758708.<br />
［34］	Saporito RC, Cohen DJ. apremilast use for moderate⁃to⁃severe atopic dermatitis in pediatric patients［J］. Case Rep Dermatol , 2016, 8（2）: 179⁃184. DOI: 10.1159/000446836.<br />
［35］	FDA approves Eucrisa for eczema. December 14, 2016. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533371.htm.<br />